Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9942108 | 1.00 | CCR1 (0.63) | CCR1NR1I2 | |
| SCHEMBL14653066 | 0.92 | CCR1 (0.75) | CCR1NR1I2 | |
| SCHEMBL12796786 | 0.92 | CCR1 (0.75) | CCR1NR1I2 | |
| SCHEMBL12398423 | 0.92 | CCR1 (0.75) | CCR1NR1I2 | |
| SCHEMBL9986625 | 0.86 | CCR1 (0.70) | CCR1 | |
| SCHEMBL9893271 | 0.86 | CCR1 (0.70) | CCR1 | |
| SCHEMBL9984607 | 0.86 | CCR1 (0.70) | CCR1 | |
| SCHEMBL12399231 | 0.86 | CCR1 (0.65) | CCR1NR1I2 | |
| SCHEMBL13676677 | 0.86 | CCR1 (0.65) | CCR1NR1I2 | |
| SCHEMBL13676795 | 0.85 | CCR1 (0.59) | CCR1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582670-B1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8642622-B2 | Piperidinyl compound as a modulator of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642622-B2 | Piperidinyl compound as a modulator of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120149733-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149733-A1 | PIPERIDINYL COMPOUND AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY | CCR2, CCR5, CCL11 | CCR1 6/4885NR1I2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.